CVS Health Corporation

CVS Health Corporation

87,294.00
CLP
+25,026.00
(+40.19%)
8,404.43EPS
Feb 17Next Earn
CVS Health Corporation
BCS:CVSCL
(Santiago Stock Exchange)

Recent

price

87,294.00

P/E

ratio

- -

div

yld

3.00%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
70.06
80.03
96.87
104.16
120.04
137.11
165.47
181.16
186.38
197.37
205.28
221.46
245.78
278.42
296.12
317.34
329.63
Revenue per Share
2.51
2.59
3.04
3.77
4
4.68
4.96
6.49
-0.57
5.1
5.48
6.07
3.29
6.49
3.66
1.4
8.65
Basic EPS, GAAP
2.03
2.98
3.65
3.12
5.17
5.52
7.38
5.97
6.54
7.99
10.26
11.94
10.25
8.09
5.02
6.16
12.2
Free Cash Flow per Basic Share
0.35
0.5
0.65
0.9
1.11
1.41
1.71
2.01
1.95
2
2
1.99
2.22
2.44
2.68
2.68
2.68
Dividend per Share
27.66
29.29
30.59
32.15
33.3
33.78
34.71
37.17
44.96
49.05
52.97
56.79
54.98
59.36
59.97
59.18
62.89
Book Value per Share
1.65
1.31
1.22
1.58
0.04
-13.43
-14.07
-14.19
-44
-37.64
-31.53
-25.02
-24.22
-34.2
-34.15
-28.14
-22.82
Tangible Book Value per Share
1,367
1,338
1,271
1,217
1,161
1,118
1,073
1,020
1,044
1,301
1,309
1,319
1,312
1,285
1,259
1,267
1,276
Basic Weighted Avg Shares
95,778
107,080
123,120
126,761
139,367
153,290
177,546
184,786
194,579
256,776
268,706
292,111
322,467
357,776
372,809
402,067
420,614
Sales/Revenue/Turnover
6.41
5.91
5.86
6.34
6.31
6.18
5.85
5.26
5.23
4.76
5.18
5.17
5.05
4.08
2.6
2.58
3.58
Operating Margin (%)
1,469
1,568
1,753
1,870
1,931
2,092
2,475
2,479
2,718
4,371
4,441
4,486
4,224
4,366
4,597
4,606
4,520
Depreciation Expense
3,427
3,462
3,864
4,592
4,644
5,237
5,317
6,622
-594
6,634
7,179
8,001
4,311
8,344
4,614
1,768
11,037
Net Income, GAAP
38.9
39.29
38.64
38.89
39.5
39.3
38.4
19.8
142.39
26.3
26.29
24.18
25.86
25.11
25.41
19.1
8.85
Effective Tax Rate (%)
3.58
3.23
3.14
3.62
3.33
3.42
2.99
3.58
-0.31
2.58
2.67
2.74
1.34
2.33
1.24
0.44
2.62
Profit Margin (%)
6,636
6,638
6,011
9,900
6,956
5,989
4,792
581
1,234
-3,001
-5,648
-7,799
-3,788
-11,331
-15,964
-13,978
-13,705
Working Capital
8,652
9,208
9,133
12,841
11,630
26,267
25,615
22,181
71,444
83,625
77,964
70,148
67,276
74,672
75,426
74,145
69,920
LT Debt
37,734
38,051
37,653
37,938
37,963
37,203
36,834
37,695
58,543
64,170
69,701
75,381
71,769
76,636
75,730
75,382
80,689
Total Equity
7.92
8.02
9.26
9.94
10.42
9.96
9.92
11.85
-1.73
6.2
6.66
6.59
4.01
6.9
4.04
2.4
8.83
Return on Invested Capital (%)
7.94
7.98
8.81
9.93
9.82
9.97
9.27
11.58
-1.73
6.22
6.05
6.48
4.08
6.91
4.35
2.76
8.89
Return on Capital (%)
9.33
9.14
10.21
12.15
12.24
13.94
14.37
17.77
-1.24
10.87
10.77
11.08
5.88
11.28
6.07
2.35
14.39
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
4,484
3,872
5,377
LT Borrowings
60,531
59,452
57,223
LT Finance Leases
13,330
12,982
12,697
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,273
1,278
1,280
Market Capitalization
91,791
87,615
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
74,817
75,346
79,392
Cash, Cash Equivalents & STI
11,802
13,958
14,887
Accounts Receivable, Net
20,144
19,380
19,595
Inventories
17,770
17,622
18,240
Total Current Liabilities
86,406
87,041
93,097
Payables & Accruals
80,847
82,160
86,816
ST Debt
4,484
3,872
5,377
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.34%
1.7%
-0.46%
Free Cash Flow
6.3%
-7.15%
23.41%
Net Income, GAAP
-133.9%
-9.5%
-61.68%
Sales/Revenue/Turnover
10.39%
8.42%
7.85%
Total Cash Common Dividend
8.3%
5.38%
0.71%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
88,437
91,234
95,428
97,710
372,809
2025
94,588
98,915
102,871
105,693
402,067
2026
100,426
106,096
108,399
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.88
1.41
0.07
1.31
3.66
2025
1.41
0.81
-3.13
2.32
1.4
2026
2.31
2.33
1.69
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.67
0.68
0.66
0.67
2.68
2025
0.67
0.68
0.67
0.67
2.68
2026
0.67
0.69
0.67
- -
- -
Business
CVS Health Corporation (CVS) operates as a diversified health solutions provider, offering integrated pharmacy, health insurance, and care services across the United States through segments including Health Care Benefits via Aetna, Pharmacy Services via CVS Caremark, and retail pharmacy operations; core products and services encompass retail pharmacies with over 9,600 locations selling prescription drugs, over-the-counter medications, health and wellness products, and general merchandise; MinuteClinic walk-in clinics providing diagnostic testing, vaccinations, and primary care; pharmacy benefit management including formulary management, claims processing, mail-order and specialty pharmacy, infusion services, and long-term care pharmacy consulting; Aetna health insurance plans covering medical, pharmacy, dental, behavioral health, and Medicare options for employers, individuals, and government programs; CVS Specialty for complex chronic disease therapies; and digital tools like mobile apps for prescription management and virtual care. Founded in 1963 and headquartered in Woonsocket, Rhode Island, the company serves approximately 100 million consumers nationwide with a workforce exceeding 300,000 colleagues, focusing on underserved communities through in-home, in-store, and virtual services. Recent developments include the completion in October 2025 of its acquisition of select Rite Aid and Bartell Drugs assets, adding 63 stores in Idaho, Oregon, and Washington plus prescription files from 626 pharmacies across 15 states to expand access for over 9 million patients; an expanded partnership with a major insurer announced in November 2025 to enhance service integration; and ongoing investments in pharmacy workforce hiring and training amid strong third-quarter 2025 financial performance with raised full-year guidance.

Company News

  • CVS says GLP-1s save money when priced below $350 per month

  • CVS Health: 3 Key Takeaways for Long-Term Investors

  • CVS Health study highlights GLP-1 benefits and the affordability challenge

  • CVS Health Corporation $CVS Stock: Aberdeen Group plc Trims Position

  • CVS Health Corporation $CVS Stock Holdings Raised by Allspring Global Investments Holdings LLC

  • CVS Breakup Won't Satisfy Washington. It Could Still Work for Wall Street.

  • Did CVS Health Corporation Insiders Breach their Fiduciary Duties to Shareholders?

  • CVS Pharmacy® launches latest collection of Caliber® Artist Series colleague-designed journals

  • Can CVS Health's 2028 Split Unlock Value Despite Execution Risks?

  • CVS Beat Earnings by 27% and Split in Two, and Elizabeth Warren Says She Is Not Fooled

  • Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock

  • Here's Why CVS Health (CVS) is a Strong Momentum Stock

  • Is CVS Stock Worth Buying as Aetna Recovers but PBM Risks Persist?

  • CVS Health Corporation (CVS) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript

  • CVS Health earns global recognition for industry-leading AI and technology innovation

  • All You Need to Know About CVS Health (CVS) Rating Upgrade to Buy

  • 1 of the Largest Corporate Splits in History Is Coming to Wall Street in 2028 -- It's a Stock Up 737% Since Its IPO

  • Mark Cuban Says the CVS Breakup Is ‘Great for Shareholders.' Here's What It Means for a 67-Year-Old Who Bought 1,000 Shares the Day the Aetna Deal Closed

  • CVS Has Not Received Offers For the Retail Pharmacy Business, CEO Says

  • CVS Health CEO Pushes Back on $1 Billion Split Cost Estimate, Outlines Growth Plans